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Transplantation Milestones 
Viewed With One- and Two-Way Paradigms of Tolerance 
Thomas E. Starzl, MD, PhD, Anthony J. Demetris, MD 
TEN YEARS ago in this journal's Land-
mark Article series of reproduced his-
torical publications, the remarkable im-
pact was described 1 ofthe 1956 report in 
J AMA by Merrill et al2 of an identical 
twin renal transplantation. The opera-
tion was performed in December 1954, 
by Joseph E. Murray (Nobel Laureate, 
1990) and his associates at the Peter 
Bent Brigham Hospital, Boston, Mass. 
By avoiding problems with rejection, 
such cases symbolized what might some-
day be accomplished if the immunologic 
reaction could be controlled. Then, on 
January 24, 1959, the barrier posed by 
genetic nonidentity was breached for 
the kidneys with a successful fraternal 
twin transplantationJ by the same team. 
Over the ensuing 35 years, the beach-
head has been expanded by the success-
ful allotransplantation of the liver,4 
heart,5Iung,6 pancreas,7 intestine,S mul-
tiple abdominal viscera,9 and bone mar-
row.lO,l! Such milestones are never 
eroded from the landscape, but their 
appearance changes as the days wear 
on. The field of organ transplantation 
has been full of such transitions as in-
sight has deepened into what actually 
has been accomplished. These shifting 
perceptions are the subject of this dis-
cussion, with emphasis on their poten-
tial future application. 
BACKGROUND 
Although details are obscure, there 
was little mystery after 1944 about the 
general meaning oftransplant rejection, 
following its elucidation by Medawar 
(N obel Laureate, 1960) as an immuno-
logic event.12 In contrast, why allografts 
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or xenografts can escape from rejection 
with or without the aid of immunosup-
pression has been one of the most ar-
cane subjects in biology ever since the 
description of acquired tolerance by Bill-
ingham, Brent, and Medawar13,14 more 
than four decades ago. 
A simple explanation for the toler-
ance in their special model was at first 
beguiling. Immunocompetent adult 
spleen cells were injected in utero or 
perinatally into mice that had not yet 
evolved the immunologic equipment to 
reject them. The engrafted cells flour-
ished, perpetuated themselves, and in 
effect endowed the recipient with the 
donor immune system. Thereafter, the 
chimeric mice failed to recognize donor 
strain skin or other tiss\ies as alien. 
THE ONE-WAY PARADIGM 
In essence, the perception of toler-
ance as a switch in immunologic appa-
ratus defined the one-way paradigm of 
transplantation immunology. The con-
cept of a unidirectional immune reaction 
in these experiments was strengthened 
by the studies of Main and Prehn15 who 
demonstrated the same outcome in ir-
radiated adult mice, whose cytoablated 
hematolymphopoietic cells were recon-
stituted with bone marrow. Hundreds 
of subsequent tolerance induction ex-
periments in animals and eventually 
clinical bone marrow transplantation 
seemingly depended on a similar natu-
ral, or iatrogenically imposed, defense-
less recipient state. 
The anticipated clinical application of 
such tolerance induction was temporarily 
derailed in 1957 when it was realized 
that an immunologically active graft could 
turn the tables and reject the recipient. 
Billingham and Brentl6 showed in their 
mouse model and Simonsen17 in chickens 
that this risk of graft-vs-host disease 
(GVHD) (also called runt disease) was 
roughly proportional to the extent of the 
major histocompatibility complex barrier. 
Such disparities became measurable in 
humans after identification of HLA by 
DaussetlB (Nobel Laureate, 1980) and by 
Terasaki and others.19 The complication 
of GVHD in rodent20 and large animal 
irradiation chimera models21-24 forestalled 
for many years the clinical use of HLA-
mismatched bone marrow cells or other 
mature immunocytes, either for immu-
nologic reconstitution for purely hema-
tologic purposes or as a means of facili-
tating whole organ graft acceptance. 
Nevertheless, a strategy for clinical 
bone marrow transplantation eventually 
was assembled directly from the rodent 
experiments, but with similar histocom-
patibility-imposed restrictions,21 After 
recipient cytoablation with total body 
irradiation or cytotoxic drugs, stable chi-
meris)"'1 could be induced in humans by 
the infusion of donor bone marrow if 
there was a good HLA match, but oth-
erwise there was an intolerable incidence 
ofGVHD. After successful engraftment, 
maintenance immunosuppression fre-
quently was not needed, mimicking the 
kind of acquired immunologic tolerance 
originally described by Billingham, 
Brent, and Medawar,13,14 and then by 
Main and Prehn.15 
The eventual success of clinical bone 
marrow transplantation in 196810•11 was 
supremely gratifying because it had been 
so logical, as Thomas (Nobel Laureate, 
1990) has summarized.21 However, the 
achievement effectively detached from 
a scientific base those who by this time 
already had recorded thousands of 
human whole organ transplantations 
(mostly kidneys) under continuous im-
munosuppression-without host precon-
ditioning, dependence on HLA match-
ing, or problems with GVHD. In the 
case described by Merrill et al in 1960,3 
the renal recipient, whose donor was his 
fraternal (dizygotic) twin brother, was 
preconditioned with sublethal total body 
irradiation. However, donor bone mar-
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Figure 1.-Two-way paradigm (organ). Bidirectional mechanism of whole organ graft acceptance involving 
a graft-vs-host (GVH) reaction by the bone marrow--<lerived donor leukocytes in the graft that are pitted 
against the whole recipient immunologic apparatus (host-vs-graft [HVG], rejection). For standard whole or-
gan clinical transplantation, the recipient is not preconditioned. 
row was not given, already a significant 
departure from the Billingham-Brent-
Medawar framework. The recipient's 
own bone marrow recovered, and the 
transplanted kidney and patient sur-
vived for 20 years. Six additional ex-
amples of protracted kidney graft sur-
vival (~l year) after recipient ir.-adia-
tion without marrow were recorded in 
Paris over the next 36 months.25,26 Five 
of the six donors were more distant than 
a fraternal twin and two were geneti-
cally unrelated.26 
These were isolated successes in a sea 
offailures. The frustration continued af-
ter the introduction for human renal 
transplantation of mercaptopurine and 
its analogue azathioprine by Murray et 
a127 following extensive experimental 
studies, first with rodent skin transplan-
tation26.29 and then with canine kid-
ney transplant models.27,30-32 The drugs 
originally had been developed as anti-
leukemic agents by Elion, Bieber, and 
Hitchings33 (Elion and Hitchings, Nobel 
Laureates, 1988) and were first demon-
strated to be immunosuppressive by 
Schwartz and Dameshek.34 
Although the sixth patient treated by 
Murray et al with one or the other of 
these myelotoxic drugs had function of 
a nonrelated renal allograft for 17 
months, the clinical results were poor at 
first,27.35 similar to those with total body 
irradiation. The tidal wave of whole or-
gan cases began in earnest in 1962 when 
azathioprine wa~. combined with pred-
nisone.36 A characteristic cycle was iden-
tified in which rejection could be re-
versed surprisingly easily with predni-
sone. More important, the need later on 
for maintenance imr.t).unosuppression fre-
quently declined Wid in occasional cases 
treatment could be stopped. The same 
sequence has been seen since with all 
other organs transplanted and with all 
of the immunosuppressive regimens. 
Agents introduced later were more po-
tent and reliable in chaperoning the de-
sired chain of events: antilymphocyte 
globulin,s7 cyclosporine,3B and tacrolimus 
(FK 506).39 Notwithstanding their di-
versity, all of the drugs seemed in a 
fundamentally similar way to have al-
lowed something to change in the host, 
the graft, or both. But what? 
Answers were not provided by the 
one-way paradigm of transplantation im-
munology that had gained ascendency 
by 1960 and remained unchallenged for 
more than 30 years. In this conceptual-
ization of a unidirectional immune re-
action, rejection of whole organs was 
construed as a mirror image of GVHD; 
the destroyers were the recipient im-
munocytes, and the allografts were the 
defenseless victims. The introduction of 
an in vitro model, the one-way mixed 
lymphocyte reaction of Bach and Hir-
schorn40 and Bain et al,41 made possible 
the detailed examination of this propo-
sition and generated thousands of in-
< 
creasingly sophisticated cellular and 
ultimatelv molecular studies of immu-
nologic r~actions. . 
However, the plethora of new infor-
mation resembled at times an exponen-
tially expanding phone book without a 
coherent theme. Most seriously, this con-
text lured successive generations of in-
vestigators into the trap of believing 
that tolerance induction for whole organ 
recipients (the "holy grail") lay in var-
iations on the HLA-limiting strategy 
used for bone marrow transplantation, 
namely, host preconditioning in prepa-
ration for a variety of donor leukocyte 
preparations .. 
THE TWO-WAY PARADIGM 
Thirty years and a revolution in im-
munology passed before a plausible ex-
planation emerged for the success of 
the empirically developed whole organ 
transplantation practices, contrary to 
the initially pessimistic predictions of 
most experts of the earlier time. In 1992, 
it was discovered in a study of pioneer 
kidney and liver recipients who were 
still extant from the early days that 
donor leUkocytes of bone marrow ori-
gin, which are part of the structure of 
all complex grafts ("passenger leuko-
cytes"),42,43 had migrated from the or-
gans and survived ubiquitously in these 
patients for up to 30 years.44,45 Thus, 
organ allograft acceptance was associ-
ated with the cryptic survival including 
stem cells of a small fragment of extra-
medullary donor marrow (depicted as a 
bone silhouette in Figure 1), which was 
assimilated into the overwhelmingly 
larger immunologic network ofthe host. 
The cell movement was in both direc-
tions, with small numbers of residual 
donor cells (microchimerism) in both the 
graft and host. 
From this information, a revision of 
transplantation immunology was pos-
sible in which the immunologic confron-
tation following whole organ transplan-
tation could be seen as bidirectional 
(GVH as well as host-vs-graft) and mu-
tually canceling, providing the two par-
ticipants in the David and Goliath mis-
match could survive the initial onslaught. 
In a clinical context, but not in several 
animal models, this survival requires an 
umbrella of immunosuppression that 
protects both cell populations equally 
(Figure 1). Current research is targeted 
to understanding the amplification de-
vice by which a small number of cells 
can so profoundly affect the immuno-
logic vision of the vast army against 
which it is arrayed. Although the chi-
meric leukocytes are multilineage,-!4-17 the 
antigen-presenting dendritic cells of 
Steinman and Cohn4<l and Steinman49 are 
thought to be critical because they can 
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Figure 2.-Two-way paradigm (bone marrow). Bidirectional paradigm in bone marrow transplantation where 
cytoablation is used to precondition the recipient. However, complete elimination of the recipient leukocyte 
population is almost never possible (see text). Note that the result in the recipient is a mirror-image version 
of whole organ transplantation (compare with Figure 1). 
modify the expression of cell interac-
tion, major histocompatibility complex, 
and adhesion molecules-all of which de-
termine how antigen signals are heeded 
by T cells.49 
With the two-way paradigm, virtu-
ally every previously enigmatic prob-
lem seen clinically after experimental or 
clinical whole organ transplantation be-
comes either transparent, or at least 
susceptible to experimental inquiry44,45: 
why HLA matching is so poorly predic-
tive of outcome, why organ grafts are 
inherently tolerogenic, and why GVHD 
does not develop after the transplanta-
tion of immunologically active grafts such 
as the liver and intestine. In addition, 
inexplicable results from a variety of 
earlier studies might be ratio:!!ally re-
interpreted. 
For example, historical efforts to give 
extra donor antigen in the form of bone 
marroW'°,51 or donor blood transfu-
sions52.54 had been hampered in design 
or execution by the assumption that the 
infused cells would be destroyed with-
out recipient preconditioning,justmable 
anxiety about GVHD if host precondi-
tioning was provided, and a lack of in-
formation about the appropriate timing 
of the infusions. The new information 
that chimerism is a naturally occurring 
event after whole organ transplanta-
tion44.45 exposed a perioperative window 
of opportunity during which unaltered 
HLA-incompatible bone marrow or do-
nor-specific blood transfusion was pre-
dicted to be safe without recipient prepa-
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ration or deviation from the generic prac-
tices of immunosuppression for whole 
organ transplantation that had evolved 
over the years from the original aza-
thioprine-prednisone formula.36 . 
The validity' ofthi~V3.trategy was veri-
fied recently in nonpreconditioned re-
cipients of cadaveric kidneys, livers, 
hearts, and lungs who were given 3 X 108/ 
kg adjuvant bone marrow cells at the 
same time as organ transplantation un-
der standard tacrolimus-prednisone 
treatment.S5 Chimerism estimated to be 
more than 1000 times that occurring in 
whole organ recipients not given bone 
marrow could be reliably and safely pro-
duced and sustained. The persistent 
blood chimerism (usually> 1 %), trend 
toward donor-specific nonreactivity, and 
high rate of patient and graft survival 
has marked the bone marrow-aug-
mented recipients as an advantaged co-
hort. They are the first to undergo HLA-
mismatched cadaveric organ transplan-
tation with the reasonable prospect of 
eventually becoming drug free. The pro-
cess of tolerance induction and drug 
weaning is expected to take 5 to 10 years 
in most patients who are given mis-
matched organs, and in some the drug-
free state may never be attainable. 
Thus, the seemingly vast gap between 
the bone marrow and whole organ trans-
plantation fields was realized to reflect 
entrenched differences of treatment 
strategy-leaving intact the mutually 
censoring immunologic limbs with or-
gan transplantation and deliberately try-
ing to remove one of the limbs for bone 
marrow grafting procedures. It is doubt-
ful that it is ever possible (much less 
desirable) with the cytoablation tech-
niques of bone marrow transplantation 
to completely eliminate the entire re-
cipient immune system (Figure 2). Al-
though this was long assumed to have 
occurred in successful cases, a trace 
population of recipient leukocytes has 
been almost invariably detected with 
sensitive techniques in patients previ-
ously thought to have complete bone 
marrow replacement.56,G7 These bone 
marrow recipients were in fact mirror 
images of successfully treated whole or-
gan recipients, the difference being'that 
their own rather than donor leukocytes 
constituted the trace population. In ei-
ther kind of patient, the appearance 
of major histocompatibility-restricted 
veto and suppressor cells, enhancing an-
tibodies, and changes in cytokine profile 
could be construed as by-products of 
and accessory to the seminal event of 
mixed chimerism (Figures 1 and 2). 
Beyond an adjuvant role for whole 
organ transplantation, an important 
question is whether HLA-mismatched 
bone marrow without an accompanying 
organ can be Emgrafted in patients whose 
disease can be corrected with a minimal 
or even microchimeric state, using the 
same immunosuppression as for marrow-
augmented kidney, liver, and heart re-
cipients, The potential list of indications 
in which complete marrow replacement 
is unnecessary is a long one, exemplified 
by the Iysozomal enzyme deficiencies. 58 
Another look into the future has been 
provided by the demonstration that xe-
nograft transplantation is followed by 
the same cell migration process as that 
seen with allografts,59 
CONCLUSION 
The fusion of whole organ and bone 
marrow transplantation into a unitarian 
world may clarify the meaning of ac-
quired transplantation tolerance. Expe-
rience from three decades of whole or-
gan transplantation has shown that the 
end result of slowly evolving narrow 
immunologic nonreactivity can be pro-
duced in humans at any age, including 
patients with undetectable or surgically 
excised thymus glands, or after sple-
nectomy. IrOnically, the explanation of 
graft acceptance via the bidirectional 
immune transaction herein described has 
direct analogies to a hypothesis proposed 
from splenocyte and bone marrow trans-
plant experiments by Simonsen60,61 and 
Michie, Woodruff, and Zeiss62 a third of 
a century ago, but abandoned because it 
could not be proved. This insight has not 
diminished the significance of the his-
torical milestones of transplantation. 
Transplantation Milestones-Starzl & LJemetris 
However, the new information has dis-
played these landmarks in a truer light 
and it should make feasible better clini-
cal strategies to achieve drug-free graft 
acceptance. 
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